Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
Clinical trial NCT03667820 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03667820
- Sponsor
- University of Texas Southwestern Medical Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-26
- Primary completion
- 2027-09-30
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.